|
Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release. |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
|
Stock and Other Ownership Interests - Teneobio |
Research Funding - Amunix (I) |
Patents, Royalties, Other Intellectual Property - Spouse is CEO of Biotech company Amunix and holds multiple technology patents for the treatment of various diseases. (I) |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; IDEAYA Biosciences; Nutcracker Therapeutics, Inc.; TeneoBio |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst) |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |